Population
Purified human rhinovirus-serotype 14 3C protease, HRV-14-infected HI-HeLa cells, and human…
Design
Preclinical
Authors
Loading...
These selective isatin derivatives merit preclinical optimization; extends HRV 3CP structural insights while leaving therapeutic potential open.
Novel isatin derivatives were designed and synthesized as reversible, nonpeptidic inhibitors of human rhinovirus 3C protease, demonstrating selective inhibition and structural validation.
Webber et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: